Compounding Updates: GLP-1 503B Bulks List & Peptides Evaluation

Recent FDA proposals and interim bulks list updates signal a clear trend toward tighter control of compounding in these high-demand therapeutic categories. As of 2026, this shift is no longer speculative but is actively unfolding through proposed exclusions, advisory committee reviews, and reclassification of multiple peptide bulk drug substances. Together, these actions are creating a more defined and restrictive framework for how certain medications can be compounded, sourced, and prescribed.

503BAna AleksicMay 18, 2026503B

Med Spa & Pharmacy Compounded Medication Due Diligence

Medication sourcing in aesthetic and wellness medicine increasingly sits at the intersection of medical spas, 503A compounding pharmacies, and 503B outsourcing facilities. Each plays a distinct but interconnected role in the supply chain. While compounding plays an essential role when commercially available products do not meet clinical needs, it also introduces additional layers of complexity. As a result, structured supplier due diligence is no longer optional.

503BAna AleksicMay 18, 2026503B, 503B Outsourcing, Med Spa

503A vs. 503B Compounding & FDA Regulations Guide

Following increased regulatory scrutiny and safety incidents linked to inconsistent oversight by state boards of pharmacy, the FDA established two designations for compounding facilities: 503A and 503B. This guide explains the defining features of each designation, the key differences between them, and what 503A compounding pharmacies and 503B outsourcing facilities need to know to remain compliant with evolving FDA and state regulations.

503Ana AleksicNovember 15, 2025503B, 503B Outsourcing, 503A pharmacies

What is a 503B? Outsourcing Facilities Explained

A 503B outsourcing facility is a type of drug manufacturing establishment authorized to compound medications in bulk, with or without patient-specific prescriptions, for distribution to healthcare facilities for office or “office-administered” use. These facilities are regulated by the U.S. Food and Drug Administration (FDA) and must comply with stringent quality and safety standards. Learn more about the definitions & regulations in this post.

Amy SummersOctober 14, 2025503B, 503B Outsourcing

503B Outsourcing Facility Market Insights: A Summary of the FDA 2022 Landscape Study Survey

The information below represents material from the conference and includes data from the 503B Market Landscape Study conducted by the FDA in 2022. These points include emerging compounding trends and key industry insights shared by FDA.

Amy SummersSeptember 23, 2022503B, MarketTrends

Current Good Manufacturing Practice—Guidance for 503B Outsourcing Facilities

Last week, the Food and Drug Administration announced the release of a revised draft guidance describing current good manufacturing practice (CGMP) requirements for 503B outsourcing facilities. The document provides direction and details as to how 503B’s can stay compliant with the Agency. Are you compliant?

Amy SummersDecember 21, 2018503B, Outsourcing Facilities, 503B Outsourcing, cGMP

503A + 503B Compounding News

© 2019-2026 restore

Info

Action